3D Epigenome in Cancer Group
The focus of the group is to understand how the three-dimensional (3D) organisation of DNA inside the nucleus relates to gene deregulation in cancer, including its cell-to-cell and temporal variability.
Central to this is understanding the role of epigenome and 3D genome alterations in driving cancer development, progression and treatment resistance, with a focus on breast and prostate cancer. For that, we combine and integrate cutting-edge genomics technology, single-cell epigenome profiling, genome editing and pre-clinical models to study the interplay of the 3D genome and epigenome in cancer.
The group has key interest in developing new epigenomic and single-cell technologies, including ongoing optimisation of chromosome conformation capture-based methods (Hi-C, Capture Hi-C, HiChIP) and bioinformatics for 3D genome structure mapping and the development of high-throughput single-cell and spatial 3D genome and epigenome profiling techniques.
- 2021Cell reports10.1016/j.celrep.2021.109722
DNA methylation is required to maintain both DNA replication timing precision and 3D genome organization integrity.
- 2020Nature communications10.1038/s41467-019-14098-x
Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer.
- 2020Nature communications10.1038/s41467-019-13753-7
Constitutively bound CTCF sites maintain 3D chromatin architecture and long-range epigenetically regulated domains.
- 2017Cold Spring Harbor symposia on quantitative biology10.1101/sqb.2016.81.031013
Alterations in Three-Dimensional Organization of the Cancer Genome and Epigenome.
Disruption of the 3D cancer genome blueprint.